MoonLake Immunotherapeutics achieves landmark milestone with positive Phase 2 results for Nanobody® sonelokimab in hidradenitis suppurativa
Posted June 27, 2023 by DSouza
MoonLake Immunotherapeutics achieves landmark milestone with positive Phase 2 results for Nanobody® sonelokimab in hidradenitis suppurativa
Feature News
-First placebo-controlled randomized trial in HS to report positive topline results using HiSCR75 as the primary endpoint
-Primary endpoint HiSCR75 met with 29 percentage points (ppt) delta vs placebo (p=0.0002) at week 12, setting a new bar in HS
-HiSCR50 met with 38 ppt delta vs placebo (p
-- END ---
Share
| Contact Email | [email protected] |
| Issued By | Knowledge Bylanes |
| Business Address | Press Centre Karachi Pakistan |
| Country | Pakistan |
| Categories | Miscellaneous |
| Tags | mir atrial |
| Last Updated | June 27, 2023 |